Yes, prestigious article that mentioned defensin Brilacidin by name, and at the end of that same article, in the concluding paragraph, the authors would not have been wrong to insert the name Brilacidin as one of the class of aforementioned defensins, yet again:
2. Conclusion
Defensins act as short cationic broad range immunostimulators to activate innate and adaptive immunity in response to infectious diseases. In respiratory viral infections, defensin abolishes viruses by inhibiting their entry, interfering with replications, and producing interleukins, cytokines, and chemokines. Also, stimulate to down-regulate the receptors essential for viral survival leading to the death of virus particles.
the the findings in the Promising Role of Defensins Peptides as Therapeutics to Combat Against Viral Infection paper, but let's call a spade a spade: Microbial Pathogenesis is hardly a 'prestigious' journal. In fact, it's an open-access journal. For those who don't know what an open-access journal is, it's where the authors pay to publish. Yes, the paper is reviewed, but it's not even close to NEJM or The Lancet in prestige. The fact we all could access the paper in its entirety, as well as the atypical language in the paper, are hallmarks of pay-to-publish journals.
News 
Market Data 
Discover 
